• Hemostemix received full approval from The Bahamas’ National Longevity and Regenerative Therapy Board for a commercial Phase 1 VesCell study.
• The clearance includes ethics approval, enabling trials targeting angina, vascular dementia, and pain within The Bahamas’ regenerative-medicine framework.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemostemix Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610071437NEWSFILECNPR____20261007_317952_1) on October 07, 2026, and is solely responsible for the information contained therein.